Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Alpha Cognition Inc
ACOG
Healthcare
Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062...
is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ACOG)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Jan 06, 2022 5:49pm
$ACOG's January presentation campaign
Alpha Cognition Inc. ( $ACOG.V $ACOGF ) had some big news this week. The biopharmaceutical company announced that they are scheduled to participate in several investor conferences this January: -
...more
(273)
•••
partystocker
X
View Profile
View Bullboard History
Post by
partystocker
on Jan 05, 2022 4:23pm
$ACOG conferences coming up
Alpha Cognition, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 22, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(144)
•••
culturedpiggy01
X
View Profile
View Bullboard History
Post by
culturedpiggy01
on Jan 04, 2022 11:14am
$ACOG.v releases packed schedule for January 2022
A bunch of exciting news released by $ACOG.v as they’ve announced that they’ll be participating in three investor conferences this January, starting the year super strong! Details below:
...more
(10)
•••
ferret_ca
X
View Profile
View Bullboard History
Post by
ferret_ca
on Dec 30, 2021 6:19pm
great bounce today
looking good finishing at or near the high for the day on a steady bounce back. If this thing pans out we will be massively rewarded, huge potential for this drug cheers and gl ferret
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Dec 30, 2021 4:33pm
$ACOG.v / $ACOGF
$ACOG.v / $ACOGF is a biopharmaceutical company currently in clinical trial for their ALPHA-1062, treating under-served neurodegenerative diseases. https://www.youtube.com/watch?v
...more
(1)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Dec 29, 2021 2:38pm
$ACOG Update
$ACOG.v $ACOGF on Monday gave an update on the company. Their team - Dr. Fred Sancilio (Director and President) is resigning and taking a smaller role - Dr. Cedric O’Gorman, the Chief Medical
...more
(273)
•••
partystocker
X
View Profile
View Bullboard History
Post by
partystocker
on Dec 26, 2021 5:38pm
$ACOG looks like a strong buy rn
Alpha Cognition is continuing to look like a strong buy in the pre-revenue biopharma market. $ACOG’s ALPHA-1062 belongs to a class of drugs that are currently the standard form of care for
...more
(144)
•••
culturedpiggy01
X
View Profile
View Bullboard History
Post by
culturedpiggy01
on Dec 23, 2021 4:10pm
$ACOG.v | studies on preventing neurodegenerative diseases
great read shared by $ACOG.v on Alzheimer’s prevention studies that suggest physical activity may be beneficial in lowering the risk of vascular dementia and Alzheimers. brain cells can benefit from
...more
(273)
•••
partystocker
X
View Profile
View Bullboard History
Post by
partystocker
on Dec 22, 2021 3:14pm
$ACOG pre-clinical results
Alpha Cognition delivered promising pre-clinical results for its ALPHA-1062 therapeutics earlier this month. Administration of the drug proved to reduce the extent of the functional deficit
...more
(10)
•••
ferret_ca
X
View Profile
View Bullboard History
Comment by
ferret_ca
on Dec 22, 2021 12:25pm
RE:$ACOG.v CEO Michael McFadden talks Alpha-1062 TBI study
well it doesn't look like the interview or presentation did anything to interest prspective buyers or trigger existing shareholders to add shares, still a bit of tax loss selling, the pushing out
...more
(144)
•••
culturedpiggy01
X
View Profile
View Bullboard History
Post by
culturedpiggy01
on Dec 21, 2021 4:07pm
$ACOG.v CEO Michael McFadden talks Alpha-1062 TBI study
great video of $ACOG.v CEO Michael McFadden talking about their Alpha-1062 Traumatic Brain Injury Study https://www.youtube.com/watch?v=-QQSJNvmUuc the inhibitor could be used to treat Alzheimer’s
...more
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Dec 20, 2021 3:26pm
CEO interview reveals $ACOG's 2022 plan (human trials etc.)
CEO of Alpha Cognition ( $ACOG.V $ ACOGF ) Michael McFadden went on the Radius Research YT channel to speak on the results from $ACOG's Alpha-1062 Traumatic Brain Injury study.
...more
(16)
•••
kindvalue
X
View Profile
View Bullboard History
Post by
kindvalue
on Dec 20, 2021 2:43pm
DELAY
anyone else notice how quietly the company delayed data to Q2 from Q1 he would not answer the question on his last presentation
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Dec 17, 2021 6:00pm
$ACOG A-1062 helps with TBI and Alzheimer's
12% of people from 80-85 are diagnosed with dementia (including Alzheimer's).Source: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian
...more
(144)
•••
culturedpiggy01
X
View Profile
View Bullboard History
Post by
culturedpiggy01
on Dec 16, 2021 4:45pm
Pharma Exec's on marketing and comm. in post Covid-19 era
came across this great article summarizing a conversation between leading pharmaceutical executives including ACOG.v 's COO Lauren D’Angelo about delivering information and communication channels
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments